Palvella Therapeutics (PVLA) Net Cash Flow (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Net Cash Flow data on file, last reported at $148.4 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 1961.87% year-over-year to $148.4 million in Q1 2026; TTM through Mar 2026 was $130.7 million, a 82.28% increase from a year earlier, with the FY2025 full-year figure at -$25.7 million, down 133.66% from the prior year.
• Net Cash Flow for Q1 2026 stood at $148.4 million, up from -$5.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for PVLA reached as high as $148.4 million in Q1 2026 and fell as low as -$33.0 million in Q1 2022.
• Historically, Net Cash Flow has averaged $8.2 million across 5 years, with a median of -$3.0 million in 2022.
• Across the five-year window, Net Cash Flow slumped 3973.4% in 2025 and jumped 1961.87% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$11.7 million in 2022, then surged by 177.69% to $9.1 million in 2023, then surged by 661.29% to $69.4 million in 2024, then sank by 107.14% to -$5.0 million in 2025, then soared by 3094.77% to $148.4 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $148.4 million in Q1 2026, -$5.0 million in Q4 2025, and -$7.7 million in Q3 2025.